Introduction
Recent history has seen a global resurgence of arboviral diseases once thought to be under control or those which have expanded their geographic distribution and disease severity such as Japanese encephalitis, tick-borne encephalitis and yellow fever, or West Nile fever and dengue, respectively (Gubler, 2002) . The recent autochthonous transmission of DENV in Key West, Florida (CDC, 2010) , a region that has not seen local dengue transmission in the past 60 years, raises awareness of the need for appropriate control measures for these viruses. DENV, viscerotropic/hemorrhagic viruses that have completely evolved to human hosts, exist as four closely related serotypes (DENV-1, to -4), and WNV, an encephalitic virus maintained in an enzootic mosquito-bird transmission cycle, are both singlestranded RNA viruses in the Flavivirus genus. DENV disease is one of the world's most important arboviral infections producing either a mild dengue fever or severe, life-threatening dengue hemorrhagic fever and shock syndrome (DHF/DSS). Severe DENV disease frequently occurs in children residing in hyperendemic countries and is strongly associated with secondary heterotypic infections (Sangkawibha et al., 1984) . WNV infection is often asymptomatic with approximately 24% of patients developing West Nile fever, and 1 in 150 symptomatic patients developing meningitis or encephalitis (Ferguson et al., 2005) . With no DENV or WNV vaccines yet available on the market, vector control and behavioral education programs are the only control methods available to reduce their public health impact.
DNA vaccination is an active field in vaccine technology following the first reports of plasmid DNA inducing an immune response to plasmid-encoded antigens (Tang et al., 1992) . Although DNA vaccines are considered an important discovery in the field of vaccinology (Mor, 1998) , they have been hampered by low immunogenicity and efficacy. Thus, various strategies to improve the immune response by DNA vaccination have been developed. Earlier attempts to increase DNA vaccine immunogenicity have included optimization of route, dosage, and timing of administration; DNA encoded or exogenously administered co-stimulatory molecules and cytokines; and differential prime-boost regimens (Leitner et al., 1999) .
We have previously described the development and protective efficacy of a WNV DNA vaccine, pVWNi, directing the expression of premembrane and envelope (prM/E) proteins that assemble to form non-infectious viral-like particles (VLP) in vivo (Davis et al., 2001) . This DNA vaccine is highly immunogenic, a single intramuscular (i.m.) injection of pVWNi protected mice and horses from WNV challenge (Davis et al., 2001) . Additionally, pVWNi confers protection in endangered California Condors and is safe and immunogenic in humans (Martin et al., 2007) . In this report, we describe the temporal kinetics of pVWNi immune protection resulting in 90-100% protection from lethal challenge in mice by 2-4 days post vaccination, respectively. In an attempt to understand this rapid protection and possibly improve the immunogenicity of DENV vaccine candidates, we screened an overlapping peptide library of the prM/E proteins of each vaccine to look for epitopes that differed between WNV and DENV-2 and identified a potent and promiscuous WNV CD4 + T cell epitope in the transmembrane domain of the WNV E protein. We introduce this T cell epitope into DENV-2 DNA and VLP vaccines and demonstrate improved immunogenicity of both vaccines through significant increases in neutralizing antibody responses. Thus, we have identified a novel, promiscuous CD4 + T cell epitope from WNV and present a strategy to introduce this epitope into heterologous flavivirus vaccines to increase their immunogenicity, an approach which may have applications for multivalent flavivirus vaccine development.
Results

pVWNi vaccination elicits rapid protection from virus challenge
Previous studies have shown three weeks post vaccination (WPV) with a single 100 μg injection of pVWNi, mice elicited high levels of WNV neutralizing antibodies which protected 100% of mice from WNV challenge (Davis et al., 2001) . To understand the temporal kinetics of the immune response to pVWNi plasmid immunization and to estimate the potential of using this vaccine as an emergency counter measurement to reduce the impact of an ongoing epidemic, C57BL/6 J mice were vaccinated with a single i.m. injection of 100 μg of DNA, and challenged with 100,000 LD 50 WNV (NY-99) at 1, 2, 4, 7, 14, or 21 days post vaccination (DPV) and compared to 1 and 21 days naïve age-matched controls. Surprisingly, 2 DPV 90% of mice survived challenge (p b 0.0001). All mice survived challenge by 4 DPV and beyond (p b 0.0001) (Fig. 1) , with the exception of the 7 DPV group (p = 0.0004) where 2 mice succumbed to lethal disease. These data suggest the pVWNi vaccine induces a rapid, protective immune response.
Vaccination induces a rapid cellular influx and activation
To investigate the causal nature of the rapid immune response and protection elicited by pVWNi vaccination, we investigated the participation of cellular immunity in the early immune response. C57BL/6J mice were vaccinated i.m. with pVWNi, pVax (vector only) and PBS as controls. Five mice per group were sacrificed at 2, 4, 7 and 14 DPV for histology and flow cytometry. Muscle from the vaccination site 4 and 7 DPV was dissected and histology performed ( Fig. 2A ). Four DPV with pVWNi, hematoxylin and eosin staining revealed a marked infiltration of cells with lymphocytic and monocytic morphology around the injection site and 7 DPV the infiltrate had mostly subsided. Mock vaccination with PBS or pVax vector control did not show any cellular infiltration suggesting pVWNi induced a transgene driven, transient cellular infiltration at the injection site. Flow cytometric analysis of single cell preparations from muscle tissue demonstrated a large proportion of the cellular infiltrate 4 DPV with pVWNi was composed of F4/80+ antigen presenting cells (APC), B220+ B cells, CD4+ and CD8+ T cells (Fig. 2B ). Antigen driven CD4+ T cells accounted for significantly higher proportions of cellular infiltrate to the injection site than did CD8+ T cells (p= 0.008). Moreover, there was a larger proportion of activated T cells (Fig. 2C) and APC (Fig. 2D ) compared to the pVax control animals (pb 0.0001) suggesting the cellular activation was transgene specific. Cytokine secretion by activated CD4+ T cells indicated Th1 and Th2 cytokine production as early as 2 DPV for IL-2, IFNγ, TNFα, and IL-4, and by 4 DPV for IL-5 (Fig. 3) . IL-2 and TNFα remained elevated through the entirety of the experiment while IFNγ and IL-4 subsided by 14 DPV. These data suggest pVWNi vaccination induces both early Th1 and Th2 cytokine profiles. Taken together, these data indicate the important role of antigen activated CD4+ T cells and F4/80+ APC in the establishment of the immune response to this vaccine.
CD4 positive epitope present in transmembrane domain of WNV envelope protein
The rapid immune response and protection elicited by the pVWNi vaccine led us to ask if there might be differential T cell epitopes that could explain some of the immunogenicity differences between the pVWNi and our previously described DENV-2 DNA vaccine that expresses DENV-2 prM, the 80% ectodomain of DENV-2 E, and the 20% stem-anchor region of JEV E (Chang et al., 2003) . The 20% JEV region was shown to enhance VLP secretion and vaccine immunogenicity compared to 100% DENV-2 E (Chang et al., 2003) . Unlike the pVWNi plasmid which only requires one 100 μg vaccination to protect 90% of mice 2 DPV (Fig. 1) , two vaccinations of 100 μg of DENV-2 plasmid 4 weeks apart were required to elicit sufficient neutralizing antibody to passively protect neonatal mice from DENV-2 challenge (Chang et al., 2003) . Although these viruses are very different in terms of their pathogenesis, growth kinetics and immunogenicity, the differences in immunogenicity between these vaccines is still remarkable despite both containing identical transcriptional enhancer and promoter, translational control element and JEV signal sequences for optimal prM translocation (Chang et al., 2003) . Based upon the above observations of the rapid cellular immune response toward pVWNi, we hypothesized that differential CD4 T cell antigenic determinants might be responsible for some of the immunogenicity differences between the WNV and DENV-2 DNA vaccines (pVD2i).
To differentiate the cellular immune responses between pVWNi and pVD2i, we constructed an overlapping peptide library covering the entire prM and E protein coding sequences of each vaccine. We initially screened the library using 23 pools of 10 15mer peptides. C57BL/6 J mice (n= 5) immunized with 100 μg of pVWNi or pVD2i were boosted at three weeks and sacrificed at 6 weeks. Spleens were homogenized, pooled, and the cells used to determine the positive peptide pools by fluorescence activated cell sorting analysis by intracellular cytokine staining. Positive peptide pools were deconvoluted and individual peptides were further tested in two independent experiments. Splenocytes from vaccinated mice were incubated with 2 μg of each individual peptide and stained for CD4 or CD8 and IFNγ. Positive peptides were compared to identify peptides unique to pVWNi or significantly different from pVD2i. Interestingly, a strong CD4+ epitopic region was identified in WNV E between amino acids 466-495 which was present, but much weaker in the 20% JEV corresponding region of pVD2i (Fig. 4) . Positive peptides in pVWNi: TQGLLGALLLWMGIN, GALLLWMGINARDRS, WMGI-NARDRSIALTF, and ARDRSIALTFLAVGG elicited 1.1, 2.5, 38.6, and 1.35% CD4+/IFNγ+ T cells, respectively. While the similar peptide region in pVD2i: QGLMGALLLWMGVNA, ALLLWMGVNARDRSI, MGVNARDRSIA-LAFL, and RDRSIALAFLATGGV elicited 1.59, 3.17, 19.9, and 1.0% CD4+/ IFNγ+ T cells, respectively. Although other peptides identified E protein epitopes with similar immunogenicity for both pVWNi and pVD2i, this region contained the only peptides differing dramatically between the two vaccines. This CD4 epitope of WNV E protein is located in two transmembrane domain (TMD) alpha helices. To our knowledge, this is the first description of a CD4 T cell epitope present in this region of any flavivirus E protein. The location of this CD4 T cell epitope could allow for manipulation of the TMD in other flavivirus vaccines since the TMD is either of low B cell antigenicity or antigenically inert (Chang et al., 2003) , B cell epitopes have not been identified in this region, and manipulation of this region will not change VLP assembly, secretion or antigenic structure. When comparing the transmembrane domains of WNV E and JEV E proteins, amino acid alignment revealed that the transmembrane domain from amino acids 466-495 are entirely conserved with the exception of four amino acids at 474, 484, 488, and 493 (Fig. 5) . Using ProPed I to predict CD8 epitopes and ProPed to predict CD4 epitopes, in silico analysis revealed the transmembrane region of WNV, amino acids 466-501, contains promiscuous CD8 and CD4 epitopes with potential to bind to several human HLA alleles. Taken together, these data suggest the incorporation of this epitope may increase the immunogenicity of DENV-2 DNA vaccination in human populations.
Incorporation of WNV CD4 epitope into pVD2i increases immunogenicity
The identification of a strong CD4 epitope in the WNV E TMD and its potential as a promiscuous human CD4 and CD8 epitope led us to investigate if this epitope could be applied to increase the immunogenicity of our DENV-2 DNA vaccine, pVD2i. Using site-directed mutagenesis we created a gain-of-function variant of the pVD2i vaccine. The four amino acids at the C-terminal 20% JEV E in pVD2i were sequentially changed to the corresponding amino acids in pVWNi. These changes produced four plasmids designated pVD2iV474I (pVD2i-I), pVD2iV474I/A484T (pVD2i-IT), pVD2iV474I/A484T/T488V (pVD2i-ITV), and pVD2iV474I/ A484T/T488V/V493L (pVD2i-ITVL). To first confirm differences in immunogenicity of the WNV CD4 TMD epitope, we utilized C57BL/6J mice, which were originally used to identify the CD4 epitope, immunized with each construct, boosted on week-4 and sacrificed on week-8. Focus reduction microneutralization (FRμNT 50 ) was performed on individual mouse sera (n=5) to assess immunogenicity between the constructs. Eight weeks post vaccination, pVD2i-I, the first amino acid change, did not significantly increase the neutralizing antibody titer (1:335) compared to pVD2i (1:261) (p= 0.20) (Fig. 6A) . However, vaccines containing the first and second, first second and third, or all four WNV amino acids elicited increased levels of neutralizing antibody (1:540, 1:434, and 1:501, respectively) with pVD2i-IT (p =0.02), and pVD2i-ITVL (p =0.04) being significant. This suggests amino acid 474 located in the first transmembrane helix may not be an integral part of the CD4 epitope as the subsequent amino acid substitutions at WNV E positions 484, 488, and 493, located in the second transmembrane helix, elicited higher levels of neutralizing antibodies compared to pVD2i. The presence of a trypsin cleavage site located between the first and second transmembrane helices which could cleave the transmembrane region into two separate peptides also supports this finding.
Based upon the observation that the WNV CD4 epitope might act as a potential promiscuous epitope and to generalize our findings, we chose to immunize outbred Swiss Webster mice (n = 10) with 100 μg of pVD2i or pVD2i-ITVL, boosted at 4 weeks, and sacrificed at 12 weeks. DENV-2 neutralizing antibody titers between the vaccines at 4 WPV did not differ, 8 WPV there was a trend for increased neutralization in the pVD2i-ITVL containing vaccine, and 12 WPV pVD2i-ITVL elicited significantly higher DENV-2 neutralizing antibody titers compared to pVD2i (p = 0.03, Fig. 6B ). This result demonstrated that the addition of the WNV TMD CD4 epitope increased the immunogenicity of pVD2i vaccine in an outbred population.
WNV CD4 epitope upregulates CD154 on CD4 T cells of pVD2i-ITVL immunized mice
Cell to cell interactions play a pivotal role in regulating the immune response. CD154 is expressed on a variety of cells (Grewal and Flavell, 1998) and is the ligand for CD40, which is expressed on B cells among others. Blocking the CD154 and CD40 interaction reveals a primary role of CD154 in regulating B cell proliferation, production of immunoglobulin (Ig), and Ig class switching (Clark et al., 1996) . To better understand the mechanism of the observed antibody increases we investigated the potential of the WNV TMD CD4 epitope to increase the expression of CD154 on CD4 T cells. Swiss Webster mice were chosen to simulate vaccination of an outbred population and immunized with 100 μg of pVD2i, or pVD2i-ITVL on weeks 0 and 4. Five mice per group were sacrificed one WPV, and the remaining 10 mice per group were sacrificed 12 WPV. Freshly harvested spleens were homogenized and stimulated for intracellular cytokine staining. One WPV splenocytes from pVD2i-ITVL vaccinated mice elicited significantly higher levels of CD154 expressing T cells (p = 0.016) compared to splenocytes from pVD2i vaccinated mice as determined by a Mann Whitney test (Fig. 7A ). In addition, stimulated splenocytes 1 WPV elicited IL-4 positive and IFNγ positive CD4 T cells suggesting the presence of both Th2 and Th1 driven T cell responses (Fig. 7B, C) . Twelve WPV, all stimulated splenocytes continue to show both Th1 and Th2 driven T cell responses, though their magnitudes were greatly reduced compared to 1 WPV. Additionally, 12 WPV CD154 expression on CD4+ T cells was reduced and no differences remained between vaccine treatments (Fig. 7) . These results imply that when introduced into the pVD2i vaccine the WNV TMD CD4 epitope functions early in the immune response to up regulate CD154 on CD4 T cells, and that this early CD154 upregulation may be the mechanism that produces the increased neutralizing antibody titers and increased immunogenicity of this vaccine modification. However, how this early increase in CD154 translates to increased neutralizing antibody titers between 8 and 12 weeks post vaccination remains unclear.
WNV CD4 epitope also increases immunogenicity of DENV VLP vaccine
Immunogenic proteins encoding neutralizing epitopes are a commonly used platform to stimulate protective immunity against many pathogens. To investigate the benefit of adding the WNV TMD CD4 epitope to protein based vaccine formats, we immunized Swiss Webster mice (n = 5) with 1 μg of purified pVD2i or pVD2i-ITVL derived VLPs. All VLP vaccines were formulated with 8% Alum, boosted at 4 weeks and sacrificed at 8 weeks. The neutralizing antibody titer of pVD2i-ITVL VLP (p = 0.02) was significantly increased compared to the pVD2i VLP vaccine (Fig. 8) . These results were qualitatively similar to those observed for the DENV-2 DNA vaccines (Fig. 6) and suggest that the incorporation of the WNV TMD CD4 epitope can increase vaccine immunogenicity for protein based vaccines in addition to DNA vaccine formats.
Discussion
We initially investigated the temporal kinetics of protection from WNV vaccination with the DNA vaccine pVWNi. Our data indicates that by 2 DPV 90% of mice were protected from lethal WNV challenge, 100% protection was achieved by 4 DPV, and that this accelerated protection was temporally correlated with the rapid influx and activation of immune cells to the injection site. Transmission of WNV through blood and organ transplantation is well documented (2002a; 2002b; 2002c) . Central nervous system involvement in WNV infection is common in immunocompromised hosts such as elderly and transplant patients. Community-acquired WNV infection has been reported following solid organ transplantation ranging from 2 months to 8 years posttransplant (Armali et al., 2003; Barshes et al., 2006; DeSalvo et al., 2004; Kumar et al., 2004) . Moreover, transplant recipients appear more likely to develop severe neurological symptoms and perhaps death, following WNV infection compared to immunocompetent hosts (Kleinschmidt-DeMasters et al., 2004; Kumar et al., 2004) . Our observations of the rapid protection induced by pVWNi and the non-infectious nature of this vaccine offer a unique target demographic for vaccination. The possibility of vaccinating transplant patients pretransplant or the high risk elderly population with prophylactic vaccination is an attractive avenue deserving further attention. Additionally, the rapid protective immunity induced by our vaccine supports the possibility of using this vaccine as an emergency counter measurement to reduce the impact of imminent or ongoing outbreaks in these high risk populations.
Several T cell epitopes have been described for the flaviviruses, many of which are localized to the non-structural proteins while fewer eptiopes have been identified in the E protein (Rothman et al., 1996; Weiskopf et al., 2011) . We have identified a potent CD4 T cell epitope in the transmembrane domain region of WNV E protein, and a much weaker CD4 T cell epitope in the corresponding 20% JEV region of our DENV-2 DNA vaccine. Consistent with our findings, a portion of this epitopic region, amino acids 481-495, has been shown to contain a potent WNV CD8 T cell epitope with protective cytotoxic capabilities (Brien et al., 2007) . The flavivirus transmembrane domain is variable between serocomplexes yet conserved within members of the same serocomplex, suggesting potential differential T cell antigenicity across the flaviviruses. The effect of such differential antigenicity of the transmembrane domain on immunogenicity and virulence between the flaviviruses is currently being investigated in our lab. Adjuvant discovery has been an active area of investigation because many non-replicating vaccine candidates are hindered by low immunogenicity and efficacy. Incorporation of the WNV TMD CD4 epitope significantly increased the immunogenicity of both pVD2i DNA and VLP vaccines. Previous attempts to increase the Fig. 4 . WNV transmembrane domain region contains a strong CD4 epitope not present in JEV. Splenocytes from mice (n = 5) vaccinated on 0 and 3 weeks with 100 μg pVWNi or pVD2i (containing C terminal 20% JEV E (Chang et al., 2003) ) were stimulated ex vivo with 2 μg of envelope peptide. Cells were stained for CD3, CD4 and IFNγ and 10,000 of the CD3/ CD4 gated population was counted. While both pVWNi-WMGINARDRSIALTF and pVD2i-MGVNARDRSIALAFL elicited IFNγ producing CD4 T cells, the response to pVWNi was greater than that of pVD2i. Dot plots are representative of a single experiment.
immunogenicity of DNA vaccination have included the use of genetic adjuvants where immunostimulatory molecules are encoded in the DNA vaccine, such as CpG motifs, cytokines, chemokines, GM-CSF, and ubiquitin (Chiarella et al., 2008) , however, long-term effects of constitutive production of such immune stimulatory molecules are unknown and still under review in clinical trials. Additional epitope adjuvants have been described using universal T cell epitopes such as tetanus toxin (King et al., 1998; Zhu et al., 2008) , pan DR epitope (PADRE) (del Guercio et al., 1997) , hepatitis B small surface antigen (Chen et al., 2010) , and heat-shock protein 70 (Lu et al., 2009 ). However, with the usage of tetanus toxin, hepatitis B and heat-shock protein 70, the development of anti-carrier immunity hindering vaccination or concurrent booster vaccinations is a possible concern.
Incorporating a naturally occurring WNV CD4 epitope into heterologous flavivirus vaccines offers advantages over these other genetic adjuvants in improving flavivirus vaccination formulation. There is limited concern of existing immunity toward the WNV TMD CD4 epitope from previous exposure interfering with the vaccine efficacy. The transmembrane domain of flaviviruses is either of low B cell antigenicity or antigenically inert, (Chang et al., 2003) and no B cell epitopes have been identified in this region. Additionally, differential T cell antigenicity between the flaviviruses can be readily manipulated, as demonstrated in this study. With the global resurgence and expansion of flavivirus disease, there is an increasing demand and utility for multivalent flavivirus vaccines beyond the generally accepted necessity of tetravalent DENV vaccines. Multivalent vaccine interference is a frequently observed phenomenon (Dagan et al., 2010; Guy et al., 2009 ). The incorporation of this naturally occurring immunodominant flavivirus epitope into live attenuated DENV vaccines could help alleviate observations of serotype-specific interference (Guy et al., 2009 ) and induce a more balanced immune response. We are currently examining the use of this WNV epitope to balance the immunogenicity of tetravalent DENV vaccines and its application to multivalent flavivirus vaccines beyond DENV deserves further investigation.
The identification of naturally occurring dominant CD4 epitopes in one component of a multivalent vaccine and the incorporation of this CD4 epitope to increase vaccine immunogenicity of a weaker component as demonstrated in this study may be a possible generalized strategy for multivalent vaccines hindered by imbalanced immunogenicity or interference. For example, serotype specific immune interference affecting immunogenicity of multivalent human papilloma virus (HPV) VLP vaccine was recently demonstrated (Zhang et al., 2010) . Licensed tetravalent vaccine containing VLP for HPV serotypes 16/18/6/11 elicited a balanced serotype specific neutralizing antibody response, while the trivalent HPV 16/18/58 displayed significant decreases in type specific neutralizing antibodies to serotype 58. Identifying and manipulating different immunogenic elements such as the CD4 T cell epitope identified here could prove a strategy to understanding and alleviating the antigenic differences between virus serotypes interfering with multivalent vaccine safety and efficacy.
Materials and methods
Vaccines
Construction and characterization of pVWNi and pVD2i DENV-2 DNA plasmid optimized with C terminal 20% JEV have been previously described Chang et al., 2003; Davis et al., 2001 ). pVWNi and pVD2i were manufactured by Aldevron (Fargo, ND). pVD2i with substitutions in the TMD, pVD2iV474I, pVD2iV474I/A484T, pVD2iV474I/A484T/T488V, and pVD2iV474I/A484T/T488V/V493L, were generated by using Quick change site-directed mutagenesis kit (Stratagene) with the following primers (Operon): 3′CGGGATGACGAGACC-TACCCGTATTTGCGTGCTCTG5′, 3′GCTAGTTACGAAACTGGAAGAATCGGT GTCCCCCACAC5′, 3′CTGGAAGAATCGGCATCCCCCACACGAGCACAAG5′, and 3′CCCCCACACGAGGACAAGAATCGCTGGTTACACG5′. These were grown in E. coli XL1 Blue cells and DNA purified by Endofree Plasmid Maxi-prep Kit (Qiagen) as per manufacturer's instructions. Structural gene elements and regulatory elements of all plasmids were sequenced entirely using a Beckman Coulter CEQ 8000 genetic analysis system (Beckman Coulter) and analyzed by Beckman Coulter CEQ 8000 (Beckman Coulter) and Lasergene software (DNASTAR). Virus-like particles (VLPs) were generated by transformation of COS-1 cells as previously described (Chang et al., 2000) and secreted VLPs were harvested from serum and animal product free media, Sfm4megavir (Hyclone). Tissue culture media was harvested, pelleted by ultracentrifugation at 19,000 rpm, concentrated 100-fold in TN buffer, pelleted by 20% sucrose cushion, and resuspended in 1/100 of original volume in TN buffer. Protein concentration was determined by Bradford Assay (BioRad) as per manufacturer's instructions. VLP vaccines consisted of 1 μg protein in 8% Alum (Thermo Scientific).
Mice C57BL/6J mice (H-2b) were purchased from Jackson Laboratory. Swiss Webster mice were purchased from Charles River. All mice were immunized i.m. with 100 μg of DNA or 1 μg of VLPs formulated with 8% Alum. C57BL/6 mice were immunized with pVWNi on day 0 and challenged with 100,000 LD 50 WNV NY99 i.p. on 1, 2, 4, 7, 14, or 21 DPV (n=10) . C57BL/6 mice were immunized with pVWNi on day 0 and sacrificed on 2, 4, 7, and 14 DPV (n =5), muscles, inguinal lymph nodes and spleens collected. C57BL/6J mice (n=5) were immunized with pVWNi or pVD2i on weeks 0 and 3, sacrificed and splenectomized on week 6. C57BL/6J mice (n =5) were immunized with pVD2i TMD constructs at weeks 0 and 4, sacrificed on week 8, splenectomized and serum collected. Swiss Webster mice (n=10) were similarly immunized and sacrificed on week 12, splenectomized and serum collected. Swiss Webster mice (n=5) were immunized with 1 μg VLP on weeks 0 and 4, sacrificed on week 8, splenectomized and serum collected. Animal experiments were approved by IACUC.
Histology
Mice were euthanized on 4 and 7 DPV and the tibialis muscle removed, fixed in 4% buffered formalin solution and sent to Colorado State University Diagnostic Laboratories for slide preparation and Hematoxylin and Eosin staining. Slides were viewed on a Zeiss microscope, at 600 × magnification.
Peptide scanning library
A library of 15 amino acid peptides with 10 amino acid overlaps was designed to cover either the envelope (E) protein or the premembrane (prM) region of WNV or DENV-2 (AC Scientific, Inc.). Peptides were arranged in pools as described previously (Betts et al., 2001; Hoffmeister et al., 2003; Kern et al., 2000; Maecker et al., 2001) . Single peptides were used at a concentration of 1 μg/ml with the total concentration of each pool being no greater than 10 μg/ml (Betts et al., 2001; Kern et al., 2000; Maecker et al., 2001) . Pool volumes were diluted in such a manner that the DMSO concentration is no greater than 1% of v/v (Hoffmeister et al., 2003) . Individual peptides were identified by pool overlap. The selected peptides went through a second round of screening. Positive peptides were determined by ex vivo stimulation of vaccinated splenocytes and demonstrated CD4+ and IFN-γ expression.
Epitope prediction of positive peptides was accomplished using online engines ProPedI (http://www.imtech.res.in/raghava/propred1/) and ProPed (http://www.imtech.res.in/raghava/propred/) setting the threshold to 1%.
Intracellular cytokine staining
Single cell suspensions were made from freshly harvested C57BL/6J or Swiss Webster spleens and plated in 96-well plates for extracellular surface antigen and intracellular cytokine staining. Splenocytes were stimulated with peptides as described above or 2 μg of UV inactivated DENV or rWNV-E (expressed in Drosophila melanogaster S2 cells generously donated by Tian Wang); PHA (Roche Diagnostics) was used as a positive control, and naïve splenocytes in cell culture medium as negative controls. 96-well plates were incubated 2 h and 1 μg of Golgi plug (BD Biosciences) was added to each well, incubated an additional 4 h before extracellular and intracellular staining.
Flow cytometry
The antibodies mouse BD Fc block, CD3, CD4, CD8, CD11b, F4/80, CD19, B220, CD80, CD28, CD154, IFNγ, TNFα, IL-2, IL-4, and IL-5 were purchased from BD Biosciences or eBiosciences. Stimulated splenocytes or single cell preparations of muscle cells were centrifuged, washed with BD Stain buffer (BD Biosciences), Fc blocked, and labeled for extracellular antigens: CD3, CD4, CD8, CD11b, F4/80, CD19, B220, CD80, CD28, or CD154. For intracellular staining CD3+/ CD4+ splenocytes were then fixed with BD cytofix/cytoperm buffer (BD Biosciences) and labeled for IFNγ, TNFα, IL-2, IL-4, or IL-5. For WNV and peptide library work, cells were analyzed using a High Performance MoFlo Cell Cytometer/Sorter and Summit version 3 software (DakoCytomation). Cells were gated on the small lymphocyte or CD3 positive population and 10,000 events were collected. For transmembrane domain replacement studies, fluorescence was detected with BD FACS Calibur and Cell quest software (BD Biosciences). The lymphocyte population was gated on a FSC and SSC plot and further gated on CD3+/CD4+, 40,000 gated events were collected and analyzed for FITC and PE positive cells. Double-positive cells from the negative control were subtracted from each sample before statistical analysis. Dot plots are representative of a single replicate.
Neutralization assay
A focus reduction microneutralization (FRμNT) technique was utilized as previously described (Crill et al., 2009 ) with few modifications. Vaccinated mouse sera were diluted 1:10, heat inactivated, titrated 2-fold to the volume of 40 μL, and 320 virus FFU/40 μL were added to each dilution. Virus strains WNV NY-99 and DENV-2 16681 were used in neutralization assays. FRμNT titers were calculated for each virus relative to a back titration. Exact FRμNT titers were modeled by the sigmoidal dose-response with variable slope using Graph Pad Prism version 4. Values are the average of two independent replicates.
Statistical analysis
All graphed original values are means +/− s.e.m. Data were compared using non-parametric Mann-Whitney or Kruskall-Wallis test. Survival data was analyzed using Kaplan-Meier survival curves. Statistical analysis performed with SAS 9.2. p b 0.05 were considered significant.
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